Author

Christoph Schumacher

Observed names: C Schumacher, C. SCHUMACHER, C. Schumacher, Christoph D. Schumacher, Schumacher, C., Schumacher, Christoph

Observed institutions: University of Bern, Novartis (Switzerland), National Institutes of Health, University of British Columbia, The University of Queensland, German Cancer Research Center, Princess Alexandra Hospital, TUM Klinikum, University Hospital Regensburg, Novartis (United States), Essen University Hospital, National Cancer Institute, Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Diakonie-Klinikum Stuttgart, Myriad Genetics, Technical University of Munich, Rockefeller University

OpenAlex ID: A5111736432

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

2012 · John R Teerlink, Gad Cotter, et al. · The Lancet · 919

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

2012 · Marco Metra, Gad Cotter, et al. · Journal of the American College of Cardiology · 427

PDF

Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities.

1991 · I. Clark-Lewis, C. Schumacher, et al. · Journal of Biological Chemistry · 426

Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils

1991 · B. Moser, C. Schumacher, et al. · Journal of Biological Chemistry · 219

High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils.

1992 · C Schumacher, I Clark-Lewis, et al. · Proceedings of the National Academy of Sciences · 191

A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution.

1995 · W T Wong, C Schumacher, et al. · Proceedings of the National Academy of Sciences · 141

Interleukin-8 antagonists generated by N-terminal modification.

1993 · B. Moser, B. Dewald, et al. · Journal of Biological Chemistry · 137

Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells

1993 · B Moser, L Barella, et al. · Biochemical Journal · 125

PDF

Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension

2012 · Adam D. Karns, Jacqueline M. Bral, et al. · Journal of Clinical Hypertension · 104

The SCAN Domain Mediates Selective Oligomerization

2000 · Christoph Schumacher, Hubert Wang, et al. · Journal of Biological Chemistry · 95

A Broad Role for the Zinc Finger Protein ZNF202 in Human Lipid Metabolism

2000 · Susanne Wagner, Mark A. Hess, et al. · Journal of Biological Chemistry · 94

PDF

Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486

2003 · Christian Honer, Kiyean Nam, et al. · Molecular Pharmacology · 91

The SH3 Domain of Crk Binds Specifically to a Conserved Proline-rich Motif in Eps15 and Eps15R

1995 · Christoph Schumacher, Beatrice S. Knudsen, et al. · Journal of Biological Chemistry · 88

PDF

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice

2009 · A. M. D. Watson, J. Li, et al. · Diabetologia · 81

PDF

Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer

2011 · Daniel Reim, Ralf Gertler, et al. · Annals of Surgical Oncology · 71

IP-10, a γ-interferon-inducible protein related to interleukin-8, lacks neutrophil activating properties

1992 · B. Dewald, B. Moser, et al. · Immunology Letters · 62

Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy

2013 · Christoph D. Schumacher, Ronald E. Steele, et al. · Journal of Hypertension · 56

Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial

2024 · Paolo Mulatero, Gregoire Wuerzner, et al. · EClinicalMedicine · 54

PDF

Aktuelle S3-Leitlinie zur Chirurgie des Magenkarzinoms

2011 · H.-J. Meyer, A.H. Hölscher, et al. · Der Chirurg · 49

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

2023 · Matthieu Faron, Maurice Cheugoua-Zanetsie, et al. · Journal of Clinical Oncology · 43

PDF

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

2024 · M. Martín, S.R. Stecklein, et al. · Annals of Oncology · 40

PDF

ZNF202 is inversely regulated with its target genes ABCA1 and apoE during macrophage differentiation and foam cell formation

2003 · Thomas Langmann, Christoph Schumacher, et al. · Journal of Lipid Research · 37

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: Correlation with outcomes

2021 · Marmor, Alon, Dorobantu, Maria, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill) · 29

PDF

CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone‐to‐renin ratio, an indicator of sodium retention, in healthy volunteers

2023 · Paolo Mulatero, Michael Groessl, et al. · British Journal of Clinical Pharmacology · 23

PDF

Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer

1999 · Evelyn Braungart, Christoph Schumacher, et al. · The Journal of Pathology · 23

Works count: 66

Citation count: 3,772

H-index: 23

I10-index: 33